



EM-No. V. 01 / 2014

Whatever your need on Oncology Clinical Trials, **ESTERN Medical** CRO Group can deliver them with excellence.



At **ESTERN Medical**, we understand that cancer is not one disease, but a category of widely varying diseases, each with its own specialized scientific complexities, patient populations, and range of treatment options.

Our Oncology Expertise is dedicated to advancing scientific knowledge and helping patients through focused, thoughtful management of critical oncology trials.

Through our Trusted Process methodology for delivering dependable trial outcomes, we have the resources, clinical expertise, and development knowhow to help our sponsors with every facet of cancer research. "We have entered an exciting age for experimental cancer therapy. Radically different approaches to clinical trial methodology are needed as we move toward a new era of targeted oncology treatments. The challenge is how best to combine monoand multi-targeted agents with conventional chemotherapy in tackling the various molecular pathways involved in cancer."

Robert Morgan, JD Head Scientific Regulatory Legal Affairs & Quality, ESTERN Medical

### SPECIALIZED EXPERTISE IN ONCOLOGY

World Health Organization statistics show that worldwide more than 11 million people are diagnosed with cancer every year. It is estimated that there will be 16 million new cases every year by 2020.

Cancer causes 7 million deaths every year or 12.5% of deaths worldwide. Yet available treatments for many types of cancer remain harsh and severely limited.

The pharmaceutical research community is engaged in an intense quest for new and better therapeutic options. We are passionately committed to this quest. We have mobilized global, multidisciplinary teams to develop and implement a broad variety of oncology research programs.

- Our Oncology Practice is led by well-experienced oncology drug developers with a thorough understanding of clinical oncology trials.
- All of our project managers and CRAs have had substantial exposure to the unique complexities of cancer research.
- We have managed Phase I-IV trials spanning a full spectrum of therapies, endpoints, and cancer indications, from protocol development through data analysis and completion of the final study report.
- Our proven, proactive recruitment methods speed enrollment and aid retention.
- We provide agency-experienced regulatory consultation for oncology research in a variety of regulatory climates.

## ACCESS TO ONCOLOGY INVESTIGATORS WORLDWIDE

- Our oncology team understands the unique challenges associated with patient accrual in cancer trials. Our seasoned oncology professionals have generated relationships with key oncology thought leaders, investigators, professional societies, cancer cooperative groups, and patient support groups. We never forget the importance of each member of the patient's medical team, or the crucial role played by the patient's family.
- We connect our sponsors to a global network of respected clinical oncologists in both private practice and academic settings.
- Our experienced staff is spread strategically throughout key countries, with critical knowledge of regional regulatory, medical, and cultural nuances.
- As the one of the first CROs to enter Latin America, we have developed long and successful relationships with research physicians and institutions in this key area.



"Latin America offers a number of advantages for running oncology clinical trials. We have oncology opinion leaders who were trained in the United States or Western Europe and came back here to practice. Our research structure and medical capabilities are comparable to the United States and Europe, there is good access to patients, with 80 percent of the Latin American population residing in a large city, great for trial recruitment"

Dr. Jorge Estrella MD. President & Chief Medical Officer

#### THE SCALE OF THE PROBLEM

In 2009, cancer was the second leading cause of death in the United States, with an estimated 562,340 deaths and 1.5 million new cases diagnosed.<sup>1</sup> United States. The US Government has called for a cancer cure in our lifetime, however, worldwide deaths from cancer are projected to continue rising to an estimated 12 million in 2030.<sup>2</sup>

There is hope, though, as the picture of how cancer develops and behaves is becoming clear for the first time.

#### **CURRENT RESEARCH TRENDS**

Pharmaceutical researchers are now working on more than 850 medicines for cancer in the United States alone.<sup>3</sup> The medicines in development, either in clinical trials or under review by the United States Food and Drug Administration (FDA).


Oncology pharmaceutical sales are projected to grow at a 6 percent Compound Annual Growth Rate from \$70.6 billion in 2009 to \$93.7 billion in 2014.<sup>4</sup>

Growth in oncology products is expected to be driven by monoclonal antibodies and targeted therapies, chemotherapeutics and blood cell factors.


#### **References:**

- 1. American Cancer Society, Cancer Facts and Figures 2009. Available at: www.cancer.org/ downloads/STT/500809web.pdf [accessed: 29/04/10]
- 2. The World Health Organization, Cancer. Available at: www.who.int/mediacentre/ factsheets/fs297/en/index.html [accessed: 29/04/10]
- 3. Billy Tauzin, Medicines in Development for Cancer. Available at: http://www.phrma.org/ files/attachments/09- 046PhRMACancer09\_0331.pdf [accessed: 29/04/10]
- 4. Cowen and Company. "Therapeutic Categories Outlook," March 2010.

#### **OUR ONCOLOGY THERAPEUTIC EXPERTISE**



# **Our Partners, Alliances & Sponsors**



Copyright, 2012 - 2014 ESTERN Medical Corporation